Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PEPITA)

    Summary
    EudraCT number
    2009-011445-13
    Trial protocol
    BE  
    Global end of trial date
    27 Nov 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    18 Apr 2025
    First version publication date
    18 Apr 2025
    Other versions
    Summary report(s)
    Final Report

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    IJB-BGDO-2009-001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00994864
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Institut Jules Bordet
    Sponsor organisation address
    Rue Meylemeersch 90, Anderlecht, Belgium, 1070
    Public contact
    Alain Hendlisz, Institut Jules Bordet, 32 2541 31 96, alain.hendlisz@gmail.com
    Scientific contact
    Alain Hendlisz, Institut Jules Bordet, 32 2541 31 96, alain.hendlisz@gmail.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    03 Dec 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Nov 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS.
    Protection of trial subjects
    The protection of trial subjects was ensured through several measures. Eligibility criteria were designed to minimize the risk of severe adverse events, and subjects had the right to withdraw at any time. Investigators were required to make clinical decisions based on their best judgment. The study team verified data to guarantee that subjects' rights and well-being were safeguarded, that trial data was accurate and verifiable, and that the trial complied with ICH-GCP guidelines, regulatory requirements, and the study protocol.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    05 Jan 2010
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Scientific research
    Long term follow-up duration
    5 Years
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 235
    Worldwide total number of subjects
    235
    EEA total number of subjects
    235
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    110
    From 65 to 84 years
    123
    85 years and over
    2

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was opened in September 2009. The recruitment period started on 05/01/2010 and ended on 18/12/2017. The principal investigators were in charge of identifying patients susceptible to be eligible for the study. They were responsible for the eligibility assessment.

    Pre-assignment
    Screening details
    Screening was done by the local investigators. In case the coordinating centre received an inclusion form corresponding to a non-eligible patient, the study PI was informed.

    Period 1
    Period 1 title
    overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded
    Blinding implementation details
    Roles blinded : Nuclearists in charge of assessing metabolic response.

    Arms
    Arm title
    Overall trial
    Arm description
    Overall trial
    Arm type
    Experimental

    Investigational medicinal product name
    FOLFOX
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection/infusion
    Routes of administration
    Infusion
    Dosage and administration details
    The FOLFOX regimen was under the PI’s discretion. The possible regimens in neoadjuvant and adjuvant settings were the same and were either: FOLFOX4: A two-hour infusion of leucovorin 200 mg/m2 followed by a 400 mg/m² bolus 5-fluorouracil (5-FU) followed by a 22-hour infusion of 5-FU 600 mg/m2 given on two consecutive days plus a two-hour infusion of 85 mg/m² oxaliplatin, on day 1, simultaneously with leucovorin. Or Modified FOLFOX6: Oxaliplatin 85 mg/m2 intravenous (IV) infusion with leucovorin 400 mg/m2 over two hours, followed by 400 mg/m2 bolus 5-FU followed by an IV infusion of 5-FU 2400 mg/m2 for 46 hours

    Number of subjects in period 1
    Overall trial
    Started
    235
    Completed
    216
    Not completed
    19
         Early AE before treatment
    2
         Second cancer
    4
         Stage IV clinically documented
    2
         Stage IV documented at baseline PET scan
    9
         Baseline hyperglycaemia
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    overall trial
    Reporting group description
    -

    Reporting group values
    overall trial Total
    Number of subjects
    235 235
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    110 110
        From 65-84 years
    123 123
        85 years and over
    2 2
    Age continuous
    Units: years
        median (inter-quartile range (Q1-Q3))
    65 (57 to 70) -
    Gender categorical
    Units: Subjects
        Female
    95 95
        Male
    140 140
    ECOG PS
    Units: Subjects
        Zero
    209 209
        One
    26 26
    Grade of differentiation
    Units: Subjects
        Well
    68 68
        Moderately
    116 116
        Poorly
    15 15
        Unknown
    36 36
    Subject analysis sets

    Subject analysis set title
    Patients evaluable (primary obj) - with metabolic response
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Patients evaluable for the primary objective : To validate the PET-assessed tumour FDG uptake response of the primary tumour after one course of preoperative chemotherapy as a predictor of outcome of adjuvant therapy, measured by 3-year DFS. The endpoint was calculated from the date of second PET scan until disease progression or death.

    Subject analysis set title
    Patients evaluable (primary obj) - without metabolic response
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Patients evaluable for the primary objective : To validate the PET-assessed tumour FDG uptake response of the primary tumour after one course of preoperative chemotherapy as a predictor of outcome of adjuvant therapy, measured by 3-year DFS. The endpoint was calculated from the date of second PET scan until disease progression or death.

    Subject analysis sets values
    Patients evaluable (primary obj) - with metabolic response Patients evaluable (primary obj) - without metabolic response
    Number of subjects
    45
    45
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    46
        From 65-84 years
    44
        85 years and over
    0
    Age continuous
    Units: years
        median (inter-quartile range (Q1-Q3))
    64 (58 to 70)
    Gender categorical
    Units: Subjects
        Female
    26
        Male
    64
    ECOG PS
    Units: Subjects
        Zero
    76
        One
    14
    Grade of differentiation
    Units: Subjects
        Well
    31
        Moderately
    45
        Poorly
    4
        Unknown
    10

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Overall trial
    Reporting group description
    Overall trial

    Subject analysis set title
    Patients evaluable (primary obj) - with metabolic response
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Patients evaluable for the primary objective : To validate the PET-assessed tumour FDG uptake response of the primary tumour after one course of preoperative chemotherapy as a predictor of outcome of adjuvant therapy, measured by 3-year DFS. The endpoint was calculated from the date of second PET scan until disease progression or death.

    Subject analysis set title
    Patients evaluable (primary obj) - without metabolic response
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Patients evaluable for the primary objective : To validate the PET-assessed tumour FDG uptake response of the primary tumour after one course of preoperative chemotherapy as a predictor of outcome of adjuvant therapy, measured by 3-year DFS. The endpoint was calculated from the date of second PET scan until disease progression or death.

    Primary: Primary endpoint

    Close Top of page
    End point title
    Primary endpoint
    End point description
    Rate disease free at 36 months
    End point type
    Primary
    End point timeframe
    The endpoint was calculated from the date of second PET scan until disease progression or death
    End point values
    Patients evaluable (primary obj) - with metabolic response Patients evaluable (primary obj) - without metabolic response
    Number of subjects analysed
    45
    45
    Units: patients
        Number of patients disease free at 36 months
    37
    29
    Attachments
    Untitled (Filename: PEPITA_FSR_chart1.png)
    Statistical analysis title
    Distribution of disease-free survival
    Statistical analysis description
    Distribution of disease-free survival according to metabolic response. Distributions for each of the 2 groups defined according to the relative evolution of SUV between baseline and after 1 cycle of chemotherapy.
    Comparison groups
    Patients evaluable (primary obj) - without metabolic response v Patients evaluable (primary obj) - with metabolic response
    Number of subjects included in analysis
    90
    Analysis specification
    Pre-specified
    Analysis type
    superiority [1]
    P-value
    = 0.06 [2]
    Method
    Unadjusted Cox regression analysis
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.6
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.33
         upper limit
    1.07
    Variability estimate
    Standard deviation
    Dispersion value
    0.31
    Notes
    [1] - Per protocol, the goal of this analysis was to assess whether metabolic response could be associated with higher disease-free survival.
    [2] - The primary analysis was unadjusted for other covariates

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    The investigators had to report all adverse events (related and unrelated) on the CRF from the pre-operative chemotherapy until 30 days after the last administration of the adjuvant chemotherapy
    Adverse event reporting additional description
    Exceptions to AE/SAE reporting. See full document for details
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Safety assessed on all patients who started treatment
    Reporting group description
    All patients who did not withdraw consent and started treatment with the first chemotherapy cycle before surgery were analysed for adverse event. Seven of the included patients were not analysed (5 patients who withdrew consent and 2 patients who did not start treatment)

    Serious adverse events
    Safety assessed on all patients who started treatment
    Total subjects affected by serious adverse events
         subjects affected / exposed
    31 / 233 (13.30%)
         number of deaths (all causes)
    27
         number of deaths resulting from adverse events
    2
    Investigations
    Blood creatinine increased
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hepatic enzyme increased
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Anastomotic fistula
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Anastomotic leak
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal anastomotic leak
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    Hypovolaemic shock
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Phlebitis superficial
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lymphopenia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Neutropenia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Splenic haematoma
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Administration site inflammation
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Extravasation
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pyrexia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    2 / 3
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Abdominal hernia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colitis
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colitis ischaemic
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colonic fistula
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diarrhoea
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Enteritis
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Enterocolitis
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal fistula
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal ischaemia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ileus
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ileus paralytic
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lower gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Peritoneal necrosis
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumatosis intestinalis
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Subileus
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acute respiratory distress syndrome
         subjects affected / exposed
    3 / 233 (1.29%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Dyspnoea
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urinary retention
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Bronchiolitis
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Endocarditis
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Genital infection fungal
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infection
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Peritonitis
         subjects affected / exposed
    3 / 233 (1.29%)
         occurrences causally related to treatment / all
    2 / 3
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    4 / 233 (1.72%)
         occurrences causally related to treatment / all
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    Prostatitis Escherichia coli
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Sepsis
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    Septic shock
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Splenic abscess
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Wound infection
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0.1%
    Non-serious adverse events
    Safety assessed on all patients who started treatment
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    164 / 233 (70.39%)
    Investigations
    Weight decreased
         subjects affected / exposed
    11 / 233 (4.72%)
         occurrences all number
    40
    Protein total
         subjects affected / exposed
    7 / 233 (3.00%)
         occurrences all number
    30
    White blood celle count decreased
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    17
    Blood magnesium decreased
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    9
    Weight increased
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    7
    Gamma-glutamyl transferase increased
         subjects affected / exposed
    5 / 233 (2.15%)
         occurrences all number
    24
    Aspartate aminotransferase increased
         subjects affected / exposed
    7 / 233 (3.00%)
         occurrences all number
    35
    Alanine aminotransferase increased
         subjects affected / exposed
    4 / 233 (1.72%)
         occurrences all number
    23
    Blood bilirubin increased
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    3 / 233 (1.29%)
         occurrences all number
    21
    Alkaline phosphatase increase
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    16
    White blood cell count increased
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Nervous system disorders
    Peripheral sensory neuropathy
         subjects affected / exposed
    104 / 233 (44.64%)
         occurrences all number
    669
    Peripheral motor neuropathy
         subjects affected / exposed
    14 / 233 (6.01%)
         occurrences all number
    47
    Paraesthesia
         subjects affected / exposed
    10 / 233 (4.29%)
         occurrences all number
    46
    Dysgeusia
         subjects affected / exposed
    12 / 233 (5.15%)
         occurrences all number
    39
    Headache
         subjects affected / exposed
    10 / 233 (4.29%)
         occurrences all number
    17
    Taste disorder
         subjects affected / exposed
    3 / 233 (1.29%)
         occurrences all number
    14
    Memory impariment
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    9
    Neuropathy peripheral
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    9
    Neurotoxicity
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    8
    Ageusia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    5
    Balance disorder
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    3
    Dizziness
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    2
    Migraine
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    2
    Syncope
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    52 / 233 (22.32%)
         occurrences all number
    311
    Anaemia
         subjects affected / exposed
    42 / 233 (18.03%)
         occurrences all number
    210
    Neutropenia
         subjects affected / exposed
    63 / 233 (27.04%)
         occurrences all number
    204
    Febrile neutropenia
         subjects affected / exposed
    5 / 233 (2.15%)
         occurrences all number
    5
    Splenic haematoma
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    99 / 233 (42.49%)
         occurrences all number
    509
    Pyrexia
         subjects affected / exposed
    6 / 233 (2.58%)
         occurrences all number
    9
    Asthenia
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    6
    Chest pain
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    4
    Pain
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    4
    Oedema peripheral
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    3
    Influenza like illness
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    2
    Catheter site pain
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Chills
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Extravasation
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Injection site inflammation
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Injection site pain
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    80 / 233 (34.33%)
         occurrences all number
    265
    Nausea
         subjects affected / exposed
    78 / 233 (33.48%)
         occurrences all number
    231
    Stomatitis
         subjects affected / exposed
    24 / 233 (10.30%)
         occurrences all number
    91
    Vomiting
         subjects affected / exposed
    18 / 233 (7.73%)
         occurrences all number
    35
    Dyspepsia
         subjects affected / exposed
    10 / 233 (4.29%)
         occurrences all number
    30
    Oesophagitis
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    13
    Abdominal pain
         subjects affected / exposed
    10 / 233 (4.29%)
         occurrences all number
    12
    Abnormal faeces
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    10
    Dysphagia
         subjects affected / exposed
    3 / 233 (1.29%)
         occurrences all number
    6
    Dry mouth
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    5
    Salivary gland pain
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    4
    Angular cheilitis
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    3
    Aphthous ulcer
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    2
    Colitis
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    2
    Flatulence
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    2
    Gastrointestinal pain
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    2
    Rectal haemorrhage
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    2
    Abdominal discomfort
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Abdominal pain upper
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Barrett's oesophagus
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Colonic fistula
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Faecaloma
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Gastrointestinal disorder
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Gingival erythema
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Intestinal ischaemia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Mouth ulceration
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Periodontal disease
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Swollen tongue
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Mucosal inflammation
         subjects affected / exposed
    4 / 233 (1.72%)
         occurrences all number
    9
    Oedema
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    2
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    13 / 233 (5.58%)
         occurrences all number
    54
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    6 / 233 (2.58%)
         occurrences all number
    19
    Prurit
         subjects affected / exposed
    4 / 233 (1.72%)
         occurrences all number
    8
    Rash
         subjects affected / exposed
    4 / 233 (1.72%)
         occurrences all number
    7
    Erythema
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    6
    Urticaria
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    6
    Dry skin
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    4
    Eczema
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    3
    Photosensitivity reaction
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Skin disorder
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Skin hyperpigmentation
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    29 / 233 (12.45%)
         occurrences all number
    78
    Hypokalaemia
         subjects affected / exposed
    4 / 233 (1.72%)
         occurrences all number
    17
    Hypoalbuminaemia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    10
    Hyperglyceamia
         subjects affected / exposed
    2 / 233 (0.86%)
         occurrences all number
    7
    Vitamin D deficiency
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    5
    Carbohydrate intolerance
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    4
    Hypomagnesaemia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1
    Hyponatraemia
         subjects affected / exposed
    1 / 233 (0.43%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    26 Nov 2009
    Modifications dates : SA1 - V1.1 27/10/2009 + EC 26/11/2009 The assessment of the predictive value of diffusion MRI on DFS has been dropped. Some minor changes in the study timeline have been made. The EuroQoL quality of life questionnaire will be additionally used. Antibodies for erbB-2 protein will also be used in circulating tumour cells and correlated with study outcomes. Addition of an exclusion criterion at screening Minor changes in study timelines Addition of Joint Study Management Team section Modification of section 18. Publication policy section: addition of the Publication Committee and authorship sections
    19 Mar 2010
    Modifications dates : SA2 - V2.0 18/01/2010 + EC 19/03/2010 + CA 09/02/2010 Update of study personnel on the first protocol page.
    03 May 2011
    Modifications dates : SA3 - V3.0 21/02/2011 + EC 03/05/2011 New version of the protocol but no modification in this protocol amendment (only a change of PI and addition of 2 new sites).
    29 Jun 2011
    Modifications dates : SA4 - V4.0 24/05/2011 + EC 29/06/2011 Suppression of the MRI sub-study FOLFOX regimen let at the investigator’s discretion
    28 May 2013
    Modifications dates : SA5 - V5.0 19/02/2013 + EC 28/05/2013 A new sentence clarifying the follow up for stage IV patients discovered at baseline or during the surgical removal of the primitive tumour has been added Change of end date of the trial due to lower than expected accrual Change of the patients’ number due to low accrual and longer follow up for these patients Adding of new translational research endpoints - To assess genomic rearrangements associated with response or resistance to FOLFOX treatment. - To identify an immunologic signature associated with metabolic tumour response to FOLFOX therapy.
    03 Oct 2016
    Modifications dates : SA8 - V6.0 05/09/2016 + EC 15/09/2016 + CA 03/10/2016 Increasing of sample size (but decrease of required number of events for the primary analysis) AE reporting section added Translational research corrections Administrative corrections
    23 Dec 2019
    Modifications dates : SA13 - V7.0 26/11/2019 + EC 23/12/2019 The translational part of the study was amended.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    There were no limitations and caveats.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:40:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA